TARO-CLOTRIMAZOLE/BETAMETHASONE DIPROPIONATE CREAM

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

BETAMETHASONE (BETAMETHASONE DIPROPIONATE); CLOTRIMAZOLE

Inapatikana kutoka:

TARO PHARMACEUTICALS INC

ATC kanuni:

D01AC20

INN (Jina la Kimataifa):

IMIDAZOLES/TRIAZOLES IN COMBINATION WITH CORTICOSTEROIDS

Kipimo:

0.05%; 1%

Dawa fomu:

CREAM

Tungo:

BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05%; CLOTRIMAZOLE 1%

Njia ya uendeshaji:

TOPICAL

Vitengo katika mfuko:

15G/50G

Dawa ya aina:

Prescription

Eneo la matibabu:

ANTI-INFLAMMATORY AGENTS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0216399001; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2020-02-19

Tabia za bidhaa

_Page 1 of 17_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TARO-CLOTRIMAZOLE/BETAMETHASONE DIPROPIONATE
Clotrimazole and Betamethasone Dipropionate Cream, USP
1% w/w clotrimazole / 0.05% w/w betamethasone (as betamethasone
dipropionate)
Topical Antifungal and Corticosteroid Agent
Taro Pharmaceuticals Inc.
Date of Revision:
130 East Drive
March 29, 2021
Brampton, ON
L6T 1C1
Submission
Control Number: 246369
_Page 2 of 17_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..........................................................3
1
INDICATIONS
..................................................................................................................3
1.1
Pediatrics....................................................................................................................3
1.2
Geriatrics
....................................................................................................................3
2
CONTRAINDICATIONS
.................................................................................................3
3
DOSAGE AND ADMINISTRATION
.............................................................................3
3.1
Dosing Considerations
...............................................................................................3
3.2
Recommended Dose and Dosage Adjustment
...........................................................3
3.3
Administration
...........................................................................................................4
4
MISSED DOSE
..................................................................................................................4
5
OVERDOSAGE
.................................................................................................................4
6
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ................5
7
WARNINGS AND PRECAUTIONS
...............................................................................5
7.1
Special Populations
...................................................